Angiotensin converting enzyme inhibition

References

• Horovitz ZP, ed. Angiotensin converting enzyme inhibitors: mechanisms of action and clinical implications. Baltimore: Urban & Schwarzenberg, 1981: 1–181
   Google Scholar
• Ferreira SH, Bartelt DC, Greene LJ. Isolation of bradykinin-potentiating peptides from Bothrops jararaca venom. Hautarzt 1969;20(11): 2583–93
   Google Scholar
• Ondetti MA, Williams NJ, Sabo EP, et al. Angiotensin-converting enzyme inhibitors from the venom of Bothrops jararaca: isolation, elucidation of structure, and synthesis. Biochemistry 1971;10(22): 4033–9
   PubMed Web of Science ®Google Scholar
• Davis JO, Freeman RH. Historical perspectives on the renin-angiotensin-aldosterone system and angiotensin blockade. Am J Cardiol 1982;49(6): 1385–9
   PubMed Web of Science ®Google Scholar
• Case DB, Atlas SA, Marion RM, et al. Long-term efficacy of Captopril in renovascular and essential hypertension. Am J Cardiol 1982;49(6): 1440–6
   PubMed Web of Science ®Google Scholar
• Atlas SA, Case DB, Sealey JE, et al. Interruption of the renin-angiotensin system in hypertensive patients by Captopril induces sustained reduction in aldosterone secretion, potassium retention and natriuresis. Hypertension 1979;1(3): 274–80
   PubMed Web of Science ®Google Scholar
• Havelka J, Vetter H, Studer A, et al. Acute and chronic effects of the angiotensin-converting enzyme inhibitor captopril in severe hypertension. Am J Cardiol 1982: 49(6): 1467–74
   PubMed Web of Science ®Google Scholar
• Raine AE, Ledingham JG. Clinical experience with Captopril in the treatment of severe drug-resistant hypertension. Am J Cardiol 1982;49(6): 1475–9
   PubMed Web of Science ®Google Scholar
• Ferguson RK, Vlasses PH, Koplin JR, et al. Captopril in severe treatment-resistant hypertension. Am Heart J 1980: 99(5): 579–85
   PubMed Web of Science ®Google Scholar
• Veterans Administration Cooperative Study Group on Antihypertensive Agents. Low-dose captopril for the treatment of mild to moderate hypertension. I. Results of a 14-week trial. Arch Intern Med 1984; 144(10): 1947–53
   PubMedGoogle Scholar
• Veterans Administration Cooperative Study Group on Antihypertensive Agents. Racial differences in response to low-dose Captopril are abolished by the addition of hydrochlorothiazide. Br J Clin Pharmacol 1982; 14(Suppl 2): 97–101S
   PubMedGoogle Scholar
• Weinberger MH. Comparison of Captopril and hydrochlorothiazide alone and in combination in mild to moderate hypertension. Br J Clin Pharmacol 1982; 14(Suppl 2): 127–31S
   Google Scholar
• Davies RO, Irvin JD, Kramsch DK, et al. Enalapril worldwide experience. Am J Med 1984;77(2A): 23–35
   PubMed Web of Science ®Google Scholar
• Bauer JH. Role of angiotensin converting enzyme inhibitors in essential and renal hypertension. Am J Med 1984: 77(2A): 43–51
   PubMed Web of Science ®Google Scholar
• Zusman RM. Renin- and non-renin-mediated antihypertensive actions of converting enzyme inhibitors. Kidney int 1984;25(6): 969–83
   PubMed Web of Science ®Google Scholar
• Gavras H. Hypertension and congestive heart failure: benefits of converting enzyme inhibition (Captopril). J Am Coll Cardiol 1983: 1(2 Pt 1): 518–20
   PubMed Web of Science ®Google Scholar
• Brunner HR, Nussberger J, Waeber B. The present molecules of converting enzyme inhibitors. J Cardiovasc Pharmacol 1985;7(Suppl 1): S2–11
   PubMed Web of Science ®Google Scholar
• Rubin PC, Millar JA, Sturani S, et al. The influence of naloxone on the circulatory effects of captopril. Br J Clin Pharmacol 1984;17(6): 713–7
   PubMed Web of Science ®Google Scholar
• Dzau VJ, Hollenberg NK. Renal response to Captopril in severe heart failure: role of furosemide in natriuresis and reversal of hyponatremia. Ann Intern Med 1984; 100(6): 777–82
   PubMed Web of Science ®Google Scholar
• Packer M, Medina N, Yushak M. Correction of dilutional hyponatremia in severe chronic heart failure by converting-enzyme inhibition. Ann Intern Med 1984; 100(6): 782–9
   PubMed Web of Science ®Google Scholar
• Dzau VJ, Colucci WS, Williams GH, et al. Sustained effectiveness of converting-enzyme inhibition in patients with severe congestive heart failure. N Engl J Med 1980: 302(25): 1373–9
   PubMed Web of Science ®Google Scholar
• Furberg CF, Yusuf S. Effect of vasodilators on survival in chronic congestive heart failure. Am J Cardiol 1985;55(8): 1110–3
   PubMed Web of Science ®Google Scholar
• Weinberger MH. Role of sympathetic nervous system activity in the blood pressure response to long-term captopril therapy in severely hypertensive patients. Am J Cardiol 1982;49(6): 1542–3
   PubMed Web of Science ®Google Scholar
• Awan NA, Amsterdam EA, Hermanovich J, et al. Long-term hemodynamic and clinical efficacy of captopril therapy in ambulatory management of severe chronic congestive heart failure. Am Heart J 1982; 103(4 Pt 1): 474–9
   PubMed Web of Science ®Google Scholar
• Captopril Multicenter Research Group. A placebo-controlled trial of captopril in refractory chronic congestive heart failure. J Am Coll Cardiol 1983;2(4): 755–63
   PubMed Web of Science ®Google Scholar
• Stumpe KO, Kolloch R, Overlack A. Captopril and enalapril: evaluation of therapeutic efficacy and safety. Pract Cardiol 1984;10(7): 111–24
   Google Scholar
• Kubo SH, Cody RJ. Enalapril, a rash, and captopril. (Letter) Ann Intern Med 1984;100(4): 616
   PubMed Web of Science ®Google Scholar
• Captopril Collaborative Study Group. Does captopril cause renal damage in hypertensive patients? Lancet 1982; 1 (8279): 988–90
   PubMed Web of Science ®Google Scholar
• Lewis EJ. Proteinuria and abnormalities of the renal glomerulus in patients with hypertension. Clin Exp Pharmacol Physiol (Suppl) 1982;7: 105–15
   Google Scholar
• Hoorntje SJ, Kallenberg CG, Weening JJ, et al. Immune-complex glomerulopathy in patients treated with captopril. Lancet 1980;1(8180): 1212–5
   PubMed Web of Science ®Google Scholar
• Erslev AJ, Alexander JC, Caro J, et al. Hematologic side effects of captopril and associated risk factors. Cardiovasc Rev Reports 1982;3(5): 660–71
   Google Scholar
• Cooper RA. Captopril-associated neutropenia: who is at risk? (Editorial) Arch Intern Med 1983; 143(4): 659–60
   PubMedGoogle Scholar
• Jenkins AC, Dreslinski GR, Tadros SS, et al. Captopril in hypertension: seven years later. J Cardiovasc Pharmacol 1985;7(Suppl 1): S96–101
   PubMed Web of Science ®Google Scholar
• Thurm RH, Alexander JC. Captopril in the treatment of scleroderma renal crisis. Arch Intern Med 1984; 144(4): 733–5
   PubMedGoogle Scholar
• Edwards CR, Padfield PL. Angiotensin-converting enzyme inhibitors: past, present, and bright future. Lancet 1985;1(8419): 30–4
   PubMed Web of Science ®Google Scholar
• Currie WJ, Cooper WD. Safety of angiotensin- converting-enzyme inhibitors. (Letter) Lancet 1985; 1(8428): 580–1
   PubMed Web of Science ®Google Scholar
• Vlasses PH, Rotmensch HH, Swanson BN, et al. Comparative antihypertensive effects of enalapril maleate and hydrochlorothiazide, alone and in combination. J Clin Pharmacol 1983;23(5–6): 227–33
   PubMed Web of Science ®Google Scholar
• Bauer JH, Jones LB. Comparative studies: enalapril versus hydrochlorothiazide as first-step therapy for the treatment of primary hypertension. Am J Kidney Dis 1984: 4(1): 55–62
   PubMed Web of Science ®Google Scholar
• Blythe WB. Captopril and renal autoregulation. (Editorial) N Engl J Med 1983;308(7): 390–1
   PubMed Web of Science ®Google Scholar
• Hricik DE, Browning PJ, Kopelman R, et al. Captopril-induced functional renal insufficiency in patients with bilateral renal-artery stenoses or renal-artery stenosis in a solitary kidney. N Engl J Med 1983;308(7);373–6
   PubMed Web of Science ®Google Scholar
• The Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The 1980 report of the Joint National Committee on Detection. Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1980;140(10): 1280–5
   PubMedGoogle Scholar
• The Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The 1984 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1984;144(5): 1045–57
   PubMedGoogle Scholar
• Drayer JI, Weber MA. Monotherapy of essential hypertension with a converting-enzyme inhibitor. Hypertension 1983: 5(5 Pt 2): 108–13
   Web of Science ®Google Scholar
• Greenberg G, Brennan PJ, Miall WE. Effects of diuretic and beta-blocker therapy in the medical research council trial. Am J Med 1984;76(2A): 45–51
   PubMed Web of Science ®Google Scholar
• Kaneko Y. Comparative study of low-dose captopril and propranolol in mild to moderate hypertension. Proc Int Soc Hypertension 1982
   Google Scholar
• Simon AC, Levenson JA, Bouthier JD, et al. Comparison of MK 421 and propranolol in mild to moderate essential hypertension and their effects on arterial and venous vessels of the forearm. Am J Cardiol 1984;53(6): 781–5
   PubMed Web of Science ®Google Scholar
• Hollenberg NK. Renal hemodynamics in essential and renovascular hypertension: influence of Captopril. Am J Med 1984;76(5B): 22–8
   PubMed Web of Science ®Google Scholar
• Daly P, Rouleau JL, Cousineau D, et al. Acute effects of captopril on the coronary circulation of patients with hypertension and angina. Am J Med 1984; 76(5B): 111–5
   PubMed Web of Science ®Google Scholar
• Medical Research Council Working Party on Mild to Moderate Hypertension. Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Lancet 1981;2(8246): 539–43
   PubMed Web of Science ®Google Scholar
• Cohn JN. Unloading the heart in congestive heart failure. Am J Med 1984;77(2A): 67–70
   PubMed Web of Science ®Google Scholar
• Packer M, Medina N, Yushak M. Contrasting hemodynamic responses in severe heart failure: comparison of captopril to other vasodilator drugs. Am Heart J 1982: 104(5 Pt 2): 1215–23
   PubMed Web of Science ®Google Scholar
• Faxon DP, Creager MA, Halperin JL, et al. Redistribution of regional blood flow following angiotensin-converting enzyme inhibition: comparison of normal subjects and patients with heart failure. Am J Med 1984;76(5B): 104–10
   PubMed Web of Science ®Google Scholar
• Dzau VJ, Colucci WS, Williams GH, et al. Sustained effectiveness of converting-enzyme inhibition in patients with severe congestive heart failure. N Engl J Med 1980: 302(25): 1373–9
   PubMed Web of Science ®Google Scholar
• Cody RJ. Angiotensin II-mediated vasoconstriction in chronic congestive heart failure, and response to converting enzyme inhibition. Am J Med 1984: 77(2A): 71–7
   PubMed Web of Science ®Google Scholar
• Nicholls MG, Ikram H, Espiner EA, et al. Hemodynamic and hormonal responses during Captopril therapy for heart failure: acute, chronic and withdrawal studies. Am J Cardiol 1982: 49(6): 1497–501
   PubMed Web of Science ®Google Scholar
• Kramer BL, Massie BM, Topic N. Controlled trial of Captopril in chronic heart failure: a rest and exercise hemodynamic study. Circulation 1983;67(4): 807–16
   PubMed Web of Science ®Google Scholar
• Franciosa JA, Wilen MM, Jordan RA. Effects of enalapril, a new angiotensin-converting enzyme inhibitor, in a controlled trial iri heart failure. J Am Coll Cardiol 1985: 5(1): 101–7
   PubMed Web of Science ®Google Scholar